Full text
Earnings transcript
Read the complete earnings call transcript.
ICLR
ICON Public Limited Company
$150.88
-0.94
(-0.62%)
| Exchange: | NASDAQ |
| Market Cap: | 11.552B |
| Shares Outstanding: | 13.929M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Barry Balfe | |||||
| Full Time Employees: | 41250 | |||||
| Address: |
| |||||
| Website: | https://www.iconplc.com |
ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. The firm excels in the strategic design, execution, and analytical oversight of programs that facilitate the entire spectrum of clinical trials, from initial compound identification through all phases (I-IV) of human studies. Its comprehensive suite of clinical development offerings encompasses early-stage drug development, strategies for patient enrollment and retention, strategic planning and data analysis, late-phase investigations, cutting-edge data and technology platforms, and expert consulting. Additionally, ICON provides specialized medical imaging, clinical research, and laboratory services; meticulous project management; efficient site monitoring and administration; robust data management; biostatistical analysis and programming; professional medical writing and publication support; medical affairs expertise; independent endpoint adjudication and data monitoring committee services; vigilant pharmacovigilance; interactive response technologies (IRT); streamlined clinical supplies logistics; strategic regulatory guidance; impactful medical communication; and broad advisory services. ICON’s diverse clientele includes companies across the pharmaceutical, biotechnology, and medical device sectors, alongside governmental and public health bodies. Established in 1990, the company maintains its headquarters in Dublin, Ireland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 8,120,176 | 8,281,676 | 8,251,340 |
| Gross Profit | 2,400,227 | 2,436,357 | 2,175,594 |
| EBITDA | 1,521,436 | 1,563,882 | 823,570 |
| Operating Income | 956,152 | 1,097,812 | 1,012,459 |
| Net Income | 612,335 | 791,474 | 229,339 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 16,989,863 | 16,877,678 | 16,269,782 |
| Total Liabilities | 7,749,120 | 7,354,679 | 7,076,398 |
| Total Stockholders Equity | 9,240,743 | 9,522,999 | 9,193,384 |
| Total Debt | 3,938,324 | 3,603,028 | 3,555,782 |
| Cash and Cash Equivalents | 378,102 | 538,785 | 647,295 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,161,027 | 1,286,652 | 1,036,205 |
| Capital Expenditure | -140,692 | -168,060 | -174,214 |
| Free Cash Flow | 1,020,335 | 1,118,592 | 861,991 |
| Net Income | 612,335 | 791,474 | 229,339 |
| Net Change in Cash | 89,334 | 160,683 | 108,510 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 9,379,665.423 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 9,573,700.449 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 9,477,500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,488,290.386 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,519,078.314 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,503,813.995 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,276,354.647 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,310,787.504 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,293,715.977 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 910,755.262 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 929,595.851 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 920,254.893 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 16.380 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 16.600 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 16.160 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: ICLR demonstrates consistent revenue growth as evidenced by historical income statements, with increasing gross profit and operating income over recent periods. Strong free cash flow generation, as shown in cash flow statements, indicates operational efficiency and the ability to fund growth initiatives without excessive reliance on external financing.
- Favorable Valuation Metrics: The current price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio from key metrics suggest ICLR is reasonably valued compared to industry averages, providing a stable investment profile. Forward P/E ratios indicate potential for sustained or improved valuation based on analyst estimates.
- Strong Market Position: As part of the healthcare sector and clinical research industry, ICLR benefits from a solid market presence, supported by a large market capitalization and a workforce of significant full-time employees, reflecting operational scale and capability.
- Positive Industry and Sector Trends: Performance data shows ICLR aligning with or outperforming industry and sector benchmarks over various timeframes (1-week to 5-year performance), highlighting resilience and competitive positioning within its peer group.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates ICLR intrinsic value between $198.23 – $240.10 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ICLR valuation
Is ICON Public Limited Company (ICLR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for ICON Public Limited Company (ICLR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ICLR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ICLR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ICLR’s P/E ratio?
You can see ICLR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ICLR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ICLR a good long-term investment?
Whether ICLR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ICLR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.62
Trading Metrics:
| Open: | 152.62 | Previous Close: | 151.82 | |
| Day Low: | 149.72 | Day High: | 154.27 | |
| Year Low: | 66.57 | Year High: | 211 | |
| Price Avg 50: | 118.37 | Price Avg 200: | 150.85 | |
| Volume: | 292451 | Average Volume: | 1.166M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeICLR full analysis
Welcome to MARKETSNAP’s SWOT analysis for ICON Public Limited Company, better known as ICON. If you’re a long-term investor looking to dig into a player in the clinical research space, you’re in the right place. Today, we’re breaking down ICON, a company that’s carved out a solid niche in the healthcare sector by providing outsourced development and commercialization services to pharmaceutical, biotech, and medical device companies. Let’s unpack what makes this company tick, dive into recent developments, and analyze its…
